Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9

Patent metadata

Field	Value
Publication number	US-11319318-B2
Application number	US-201615554440-A
Country	US
Kind code	B2
Filing date	Mar 4, 2016
Priority date	Mar 5, 2015
Publication date	May 3, 2022
Grant date	May 3, 2022

Abstract

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R9, X1 and X2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. cancer, pharmaceutical preparations containing such compounds and their uses as a medicament.

First claim

The invention claimed is:

1. Compound

or its salts.

2. A pharmaceutical preparation containing as active substance the compound of claim 1 or a pharmaceutically acceptable salt thereof—optionally in combination with conventional excipients and/or carriers.

3. Compound

or its salts.

4. Compound

or its salts.

5. A pharmaceutical preparation containing as active substance the compound of claim 3 or a pharmaceutically acceptable salt thereof—optionally in combination with conventional excipients and/or carriers.

6. A pharmaceutical preparation containing as active substance the compound of claim 4 or a pharmaceutically acceptable salt thereof—optionally in combination with conventional excipients and/or carriers.

Assignees

• Boehringer Ingelheim Int

Inventors

• Martin Laetitia
• Steurer Steffen
• Cockcroft Xiao-Ling

Classifications

• C07D213/64

  attached in position 2 or 6 · CPC title

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D237/32

  with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring · CPC title

• C07D217/24

  Oxygen atoms · CPC title

• C07D487/08

  Bridged systems · CPC title